ArticleScience (New York, N.Y.)2017
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.
Erratum issued Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07387861 (Immunohistochemical Evaluation of p-AKT and p-S6 as Surrogate Markers of PI3K/AKT/mTOR Pathway Activation in ER-Positive, HER2-Negative Breast Carcinoma), which is not on this map. Cited by 172 papers.
0numbers the graph read from it
0cells of the map it votes in
172citing papers in PubMed
13.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunohistochemical Evaluation of p-AKT and p-S6 as Surrogate Markers of PI3K/AKT/mTOR Pathway Activation in ER-Positive, HER2-Negative Breast Carcinoma
Who cites it
172 citing papers in PubMed, 264 citations in OpenAlex.
- Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2021Trial
- Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.The Lancet. Oncology · 2020Trial
- BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Trial
- Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Trial
- PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance.The Journal of clinical investigation · 2026Review
- Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer.Molecular cancer therapeutics · 2026Article
- Integrated Interactomics Reveals Novel Protein Associations: The FOXA1-PBX1 Complex as a Case Study.bioRxiv : the preprint server for biology · 2026Article
- Histone methyltransferase KMT2D promotes castration-resistant prostate cancer progression by reactivating AR through FOXA1.Oncogene · 2026Article
- Enhancer and metabolic rewiring by KMT2C-COMPASS or KMT2D-COMPASS family loss in cancer creates druggable vulnerabilities.Nature reviews. Cancer · 2026Review
- A renaissance in targeting the PI3K/AKT/mTOR pathway.Nature reviews. Drug discovery · 2026Review
- Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation.Signal transduction and targeted therapy · 2026Article
- The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer.Cancer research · 2026Article
- Contrasting roles of KMT2C and KMT2D in breast cancer.Scientific reports · 2025Article
- eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- [Genetic profiling of parathyroid tumours: lifting the veil of mystery].Problemy endokrinologii · 2025Review
- Sex-Specific Concordance of Striatal Transcriptional Signatures of Opioid Addiction in Human and Rodent Brains.Biological psychiatry global open science · 2025Article
- The Role of the Fox Gene in Breast Cancer Progression.International journal of molecular sciences · 2025Review
- Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia.Blood neoplasia · 2025Article
- Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma.Nature communications · 2024Article
- Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers.Molecular cancer · 2024Article
112 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
11 authors at 2 institutions in 2 countries.
Eneda ToskaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.ORCID 0000-0002-8974-9792
Hatice U OsmanbeyogluComputational Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 460, New York, NY 10065, USA.
Pau CastelHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.ORCID 0000-0002-4972-4347
Carmen ChanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.ORCID 0000-0001-9086-6622
Ronald C HendricksonMicrochemistry and Proteomics Core Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-6899-7287
Moshe ElkabetsHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.ORCID 0000-0003-3634-9098
Maura N DicklerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Maurizio ScaltritiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.ORCID 0000-0002-5522-1447
Christina S LeslieComputational Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 460, New York, NY 10065, USA.ORCID 0000-0002-4571-5910
Scott A ArmstrongCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-9099-4728
José BaselgaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.ORCID 0000-0003-1361-4063
Memorial Sloan Kettering Cancer Center · USBen-Gurion University of the Negev · IL
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI DANIEL J DEANGELO · 1996 to 2026
$52.5MUnraveling resistance to PI3K-alpha inhibitors in breast cancerR01CA190642 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCALTRITI, MAURIZIO · 2015 to 2019
$2.2MMolecular pathogenesis of MLL-AF4 leukemiasR01CA140575 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ARMSTRONG, SCOTT A · 2010 to 2014
$1.7MLTQ-ORBITRAP VELOS Tandem Mass SpectrometerS10OD010598 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI HENDRICKSON, RONALD CHARLES · 2012 to 2012
$460kAlgorithms to link signaling pathways with transcriptional programs for precision medicineK99CA207871 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI OSMANBEYOGLU, HATICE ULKU · 2016 to 2017
$270kNCI NIH HHS K99 CA207871NCI NIH HHS P01 CA066996NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA140575NCI NIH HHS R01 CA190642NIH HHS S10 OD010598
Abstract
Activating mutations in
Indexed as
Epigenesis, GeneticTranscription, GeneticAnimalsBreast NeoplasmsChromatinClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsFemaleHEK293 CellsHepatocyte Nuclear Factor 3-alphaHumansLysineMCF-7 CellsMetabolic Networks and PathwaysMethyltransferasesMiceAKT1 protein, humanChromatinClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaKMT2D protein, humanLysineMethyltransferasesNeoplasm ProteinsPBX1 protein, humanPIK3CA protein, humanPre-B-Cell Leukemia Transcription Factor 1Proto-Oncogene ProteinsProto-Oncogene Proteins c-aktReceptors, Estrogen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07387861ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.